ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2013
Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research.
Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Burkitt and Burkitt-Like Lymphomas: a Systematic Review.Current oncology reports · 2020Pooled it
- Novel devimistat results in complete remissions in heavily pretreated Burkitt lymphoma in a phase 2 trial.Blood advances · 2025Trial
- CAR19/22 T cell therapy in adult refractory Burkitt's lymphoma.Cancer immunology, immunotherapy : CII · 2021Trial
- Hematopoietic stem cell transplantation in children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma.International journal of hematology · 2019Trial
- Durable Response to Glofitamab in HIV-Positive Refractory Burkitt Lymphoma: Case Report and Discussion.EJHaem · 2026Article
- Novel Molecular Insights and Evolution of Less Toxic Therapeutic Strategies in Burkitt Lymphoma.Cancers · 2025Review
- Phosphatidylinositol 3-Kinase Inhibition and Allogeneic Stem Cell Transplantation Can Overcome Chemotherapy Resistance in Refractory Burkitt Lymphoma.Journal of hematology · 2025Article
- [Rituximab combined with intensive immunochemotherapy for sporadic adult Burkitt lymphoma: efficacy and prognosis analyse].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- Human immunodeficiency virus-associated Lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.HemaSphere · 2024Article
- The Treatment of Burkitt Lymphoma With the Berlin-Frankfurt-Münster Protocol With Rituximab and Consolidative Autologous Transplantation.The oncologist · 2024Article
- Refractory Burkitt Lymphoma: Diagnosis and Interventional Strategies.Blood and lymphatic cancer : targets and therapy · 2024Review
- Case report: A novel third-generation anti-CD19/CD22 CAR T-cells combined with auto-HSCT for relapsed Burkitt lymphoma.Frontiers in immunology · 2024Article
- Chemotherapy resistant Burkitt lymphoma: Possible novel therapies including CAR-T cell infusion.Clinical case reports · 2023Article
- EBV and Lymphomagenesis.Cancers · 2023Review
- Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study.Haematologica · 2021Article
- Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for malignant lymphoma 2021 (English version).Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2021Article
- Article
- Cryostorage to What End? - Autologous Stem Cell Products in Burkitt Lymphoma, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Myeloproliferative Neoplasm Patients.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2021Article
- Burkitt lymphoma: bridging the gap between advances in molecular biology and therapy.Leukemia & lymphoma · 2020Review
- [Rituximab combined with short-course and intensive regimen for Burkitt leukemia: efficacy and safety analysis].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 19 institutions in 4 countries.
Funding
Abstract
Trends in utilization and outcomes after autologous or allogeneic hematopoietic cell transplantation (HCT) for Burkitt lymphoma were analyzed in 241 recipients reported to the Center for International Blood and Marrow Transplant Research between 1985 and 2007. The autologous HCT cohort had a higher proportion of chemotherapy-sensitive disease, peripheral blood grafts, and HCT in first complete remission (CR1). The use of autologous HCT has declined over time, with only 19% done after 2001. Overall survival at 5 years for the autologous cohort was 83% for those in CR1 and 31% for those not in CR1. Corresponding progression-free survival (PFS) was 78% and 27%, respectively. After allogeneic HCT, overall survival at 5 years was 53% and 20% for the CR1 and non-CR1 cohorts, whereas PFS was 50% and 19%, respectively. The most common cause of death was progressive lymphoma. Allogeneic HCT performed in a higher-risk subset (per National Comprehensive Cancer Network guidelines) resulted in a 5-year PFS of 27%. Autologous HCT resulted in a 5-year PFS of 44% in those undergoing transplantation in the second CR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.